Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

An unusual public feud between the Food and Drug Administration and a maker of gene therapies for rare diseases could test ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Wall Street awaits earnings Monday from Verizon.

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Resorts in Spain and Portugal are the most popular destinations for UK holidaymakers this summer, according to a new report.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with ...